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Abstract
Background: The ex vivo expansion potential of mesenchymal stromal/stem cells (MSC) together with their differentiation
and secretion properties makes these cells an attractive tool for transplantation and tissue engineering. Although the use of
MSC is currently being tested in a growing number of clinical trials, it is still desirable to identify molecular markers that may
help improve their performance both in vitro and after transplantation.
Methods: Recently, HOXB7 was identified as a master player driving the proliferation and differentiation of bone marrow
mesenchymal progenitors. In this study, we investigated the effect of HOXB7 overexpression on the ex vivo features of
adipose mesenchymal progenitors (AD-MSC).
Results: HOXB7 increased AD-MSC proliferation potential, reduced senescence, and improved chondrogenesis together
with a significant increase of basic fibroblast growth factor (bFGF) secretion.
Conclusion: While further investigations and in vivo models shall be applied for better understanding, these data suggest
that modulation of HOXB7 may be a strategy for innovative tissue regeneration applications.
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Introduction
Mesenchymal stromal/stem cells (MSC) are progenitor
cells that have been isolated and expanded from a wide
range of tissues [1–7]. Their ability to differentiate and
secrete supporting factors makes them attractive thera-
peutic tools for regenerative medicine [8]. For these
reasons, MSC transplantation has received increased
attention in different clinical settings [9, 10]. Progress in
preclinical models and recent data obtained from clinical
trials have demonstrated the therapeutic potential of
MSC in tissue regeneration and repair. However,
significant questions remain [11]. In particular, the role
of MSC and their biological behavior in different physio-
logical and pathological conditions in humans need to
be clarified aiming for a more solid therapeutic impact.
For this reason, it is important to dissect the behaviors
and functions of MSC in these different contexts to iden-
tify the molecular players that may help improve the
performance of MSC ex vivo or after transplantation [12].
It is known that aging is a complex process that
involves every cell and organ of the body and leads to
the degeneration of many functions over a lifespan.
Tissues progressively lose their regenerative and homeo-
static ability with age. The homeostatic and regenerative
activities of these tissues can be attributed to the resident
stem cells. The age-related changes may be reflections of a
decline in stem cell function [13]. However, the mecha-
nisms underlying the control of the aging process in
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human cells remain poorly understood, which has an
impact on the development of cell-based therapies.
By focusing on epigenetic regulation, we discovered
that miR-196 is one of the molecular markers that deter-
mine the changes in MSC during aging [14]. Starting
from miR-196, we identified HOXB7 as an age-related
gene that is inversely correlated with senescence in vitro
and in vivo. HOX genes are fundamental components of
embryonic patterning and morphogenesis with persistent
expression into adulthood. Several studies support the
involvement of HOX genes at several levels along the
stem cell hierarchy, including positional identity, stem
cell self-renewal, and differentiation [15–17]. HOX genes
have been investigated in a variety of progenitor cells
and it has been suggested their role in proliferation,
differentiation, and senescence [18–22].
When we forced HOXB7 expression in primary bone
marrow MSC (BM-MSC), we observed that HOXB7 sig-
nificantly increased cell proliferation by an unclear
mechanism, which we originally related to an autocrine
bFGF loop. Furthermore, forced HOXB7 expression re-
duced senescence, suggesting that HOXB7 might impact
aging in addition to in vitro senescence. Therefore, in the
present study, we investigated whether HOXB7 over-
expression affected other well-known MSC sources, such
as adipose-derived MSC (AD-MSC) in an attempt to
demonstrate the role of HOXB7 in other mesenchymal
cell populations. Adipose tissue represents a valid re-
servoir of mesenchymal progenitors [23–25]. Adipose
tissue can be obtained in a significant amount under
local anesthesia with minimum patient discomfort
and can be easily processed to release large numbers
of AD-MSC. Therefore, it represents a suitable tool for
tissue regeneration and gene therapy approaches [26].
Thus, the aim of this study has been to analyze the impact
of HOXB7 overexpression on AD-MSC investigating
whether its influence on AD-MSC is comparable to the
one observed with BM-MSC. This would allow a better
understanding of whether HOXB7 may impact on a
variety of mesenchymal progenitors’ performance.
Materials and methods
Isolation and expansion of AD-MSC
AD-MSC were obtained from lipoaspirate specimens
(n = 3 collected between hips/thighs, abdomen, or glu-
teal region) from individuals (three Caucasian females
ranging from 44 to 66 years old) undergoing liposuc-
tion for esthetic purposes at the Plastic Surgery Unit,
University-Hospital of Modena and Reggio Emilia. In-
formed consent was obtained, and the study was approved
by the local Ethical Committee. All AD-MSC samples
were isolated and expanded, and cumulative population
doubling (CPD) was calculated as previously reported
[27]. RNA extraction, immunophenotypical analysis, and
differentiation assays were performed after four culture
passages (P4) as described below.
MigRI-HOXB7 vector for viral infection
The bi-cistronic murine stem cell virus-derived retroviral
vector (pMIGR1) encoding the green fluorescence protein
(GFP) was modified to carry HOXB7 (NM_004502.3), as
previously described [14]. The coding sequence was
amplified from total human RNA using primers with
short extensions containing cleavage sites for BglII (5′ end)
and EcoRI (3′ end): HOXB7 forward (5′-TATCAGATC
TAAATCATCCGGCCAAATTATGAG-3′) and HOXB7
reverse (5′-TATCGAATTCTGCCCTTTCTCCATCCCTC
AC-3′). The amplicons were cleaved with BglII and EcoRI
and cloned into the BglII and EcoRI sites of the MigR1
(MSCV-GFP) vector. The resulting vector was defined
as pMIGR1-HOXB7. The empty MIGR1-GFP vector
was used as a control. Retrovirus production was per-
formed using the FLYRD18 packaging cell lines as pre-
viously described [26].
FACS analysis
Cell surface antigen expression was investigated in the
control cell population, represented by AD-MSC-GFP and
HOXB7-overexpressing AD-MSC. The following panels
of monoclonal antibodies were assessed: APC-anti-CD45,
PE anti-CD14, PE anti-CD73, and PE anti-HLA-DR (BD
Pharmigen, San Diego, CA, USA); APC-anti-CD146
(MACS, Miltenyi Biotec Bergisch Gladbach, Germany);
APC-anti-CD90 and APC-anti-CD105 (eBioscience, San
Diego, CA, USA); and isotype controls (BD Biosciences
and BioLegend, San Diego, CA, USA). Samples were ana-
lyzed using the FACSAria III flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). The data were ana-
lyzed using DIVA software (Becton Dickinson, Franklin
Lakes, NJ, USA). Cell cycle distribution was evaluated
by propidium iodide (PI) staining. Single suspensions of
1 × 106 AD-MSC-GFP or AD-MSC-HOXB7 at passage
12 were fixed with ice-cold 70% ethanol and stored at
− 20 °C overnight. Cells were washed in PBS and resus-
pended in 200 μl of Cell Cycle Solution containing PI,
RNase A, and Triton X-100 (Invitrogen, Molecular
Probe, USA). The samples were then incubated for 30
min at room temperature in the dark and analyzed by
FACSAria III and DIVA software.
RNA extraction and cDNA synthesis
Total cellular RNA was isolated using TRIzol® (Invitrogen,
Carlsbad, MN, USA) according to the manufacturer’s
instructions. First-strand complementary DNA (cDNA)
was synthesized from 2 μg total RNA using the RevertAid
H minus first-strand cDNA synthesis kit (Fermentas -
ThermoFisher, Waltham, MA, USA). The cDNA was
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quantified using a spectrophotometer (Beckman Coulter
DU® 730, Pasadena, CA, USA).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed
using the Applied Biosystems StepOne™ Real-Time PCR
System and the Fast SYBR® Green Master Mix reagent.
The qRT-PCR reaction (10 μl) consisted of 50 ng cDNA,
Fast SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA), and 300 nM of the forward and
reverse primers. Primer sequences are presented in
Table 1. Relative target gene expression levels were
calculated by the 2-ΔΔCt (cycle threshold) method
using the human β-actin gene as the control gene [28].
β-Galactosidase staining
pH-dependent senescence-associated β-galactosidase
activity (SA-β-gal) was analyzed using the SA-β-gal
staining kit (Cell Signaling Technology, Boston, MA,
USA). AD-MSC were seeded at 5500/cm2 in triplicate in
a 6-well plate. When the cells reached 60 to 70% conflu-
ence, they were stained for SA-β-gal according to the
manufacturer’s instructions. Positive cells were counted
in independent fields (n = 10) for each sample at × 2.5
magnification.
ELISA
The bFGF levels in the AD-MSC samples were mea-
sured using the Quantikine human bFGF kit (R&D
Systems, 614 McKinley Place NE, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
This assay employs the quantitative sandwich enzyme
immunoassay technique.
Differentiation assays
The differentiation potential of AD-MSC for three line-
ages was assessed as previously reported [27]. For osteo-
genic induction, AD-MSC were seeded in conditioning
medium for 2 weeks. The osteogenic medium for the
first week consisted of α-MEM supplemented with 8%
(v/v) plate lysate (PL) and inducing agents (10 mM
β-glycerophosphate, 0.1 mM ascorbic acid-2-phosphate,
and 10 nM dexamethasone (Sigma-Aldrich). For the
second week, 100 ng/ml rhBMP-2 (Peprotech, UK) was
added to the osteogenic medium. Osteogenic differen-
tiation was assessed by von Kossa staining of the cul-
tured cells that were fixed in ice-cold methanol for
2 min, rinsed in distilled water, and incubated with 1%
silver nitrate for 30 min under a UV lamp. The stained
samples were washed and then visualized at ELISA × 10
magnification using an inverted microscope (Zeiss). The
Table 1 Primers used to perform qRT-PCR
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percentage of von Kossa-stained cells was calculated
using ImageJ software (http://rsb.info.nih.gov/ij). For
chondrogenic differentiation experiments, the cells were
pelleted by centrifugation and incubated at 37 °C with
5% CO2 in a humidified incubator (lid not closed). To
test the chondrogenic differentiation potential of trans-
duced and non-transduced AD-MSC, the cells were
maintained in DMEM high glucose (Gibco by Life Tech-
nologies, Paisley, UK) containing 1% penicillin/strepto-
mycin (Carlo Erba, Rodano (MI), Italia); 500 ng/mL
BMP-6 and 10 ng/mL TGF-β (Peprotech, Rocky Hill, NJ,
USA); BD ITS™ + Premix (BD Biosciences); 100 nM
dexamethasone, 0.2 mM ascorbic acid-2-phosphate, and
40 μg/mL proline (Sigma-Aldrich, St. Louis, MO, USA);
and 100 μg/mL sodium pyruvate (Biochrom). After 21
days of induction, the samples were inserted into para-
ffin blocks and cut into 4-μm sections for Safranin O
and Fast Green staining. Slides were evaluated using
light microscopy (Axiovert 200M, Zeiss).
To test the adipogenic differentiation potential of the
transduced and non-transduced AD-MSC, the cells were
maintained in DMEM low glucose (Gibco by Life Tech-
nologies, Paisley, UK) containing 1% glutamine (Lonza,
Verviers, Belgium), 1% penicillin/streptomycin (Carlo
Erba, Rodano (MI), Italia), 10% rabbit serum (EuroClone,
Pero (MI), Italy), 5% horse serum (EuroClone, Pero (MI),
Italy) and 1 μM dexamethasone, 60 μM indomethacin,
10 μM recombinant human insulin, and 0.5mM isobutyl
methyl xanthine (Sigma, St. Louis, MO, USA). All culture
plates were incubated at 37 °C with 5% CO2. The cells
were induced for 10 days, and lipid droplets were detected
by Oil Red O staining (Sigma, St. Louis, MO, USA) using
light microscopy (Axiovert 200M, Zeiss).
Immunohistochemistry
Chondrogenic differentiation was tested by immunohisto-
chemistry by anti-aggrecan (ACAN) and anti-Collagen
2A1 (Col2A1) antibodies. Paraffin sections (4-mm thick)
were dehydrated and stained by rabbit anti-human Col2A1
(1:75; Novus Biologicals, Centennial, CO, USA) and by
rabbit anti-human ACAN (1:1000; Abcam, Cambridge,
UK) combined with a goat anti-rabbit biotinylated second-
ary antibody (Ab) (1:200; Vector Laboratories, Burlingame,
CA, USA) and detected by an avidin-biotin-horseradish
peroxidase system (Vector Laboratories). Antigen retrieval
was performed by proteinase K, 1× (Promega Corporation,
Madison, WI, USA) treatment for 5min at room
temperature, blocking nonspecific binding with 10%
new-calf serum blocking reagent (Sigma-Aldrich, St. Louis,
MO, USA). Primary antibodies in 0.1% bovine serum albu-
min (Sigma-Aldrich) and 10% normal goat serum (Vector
Laboratories) were applied overnight. After secondary Ab
(Vector Laboratories) incubation and quenching, slides
were incubated with Vectastain ABC (Vector Laboratories)
as suggested by manufacturer instructions. Color develop-
ment was performed by Peroxidase Substrate Kit DAB
(Vector Laboratories) and slides were counterstained with
Mayer’s Hematoxylin (Sigma-Aldrich). Isotype control was
stained with only secondary Ab. Stained slides were then
examined by Zeiss Axioskop (Zeiss) and photomicrographs
were acquired by Axiocam IcC3 color camera and Axiovi-
sion 4.82 software visualization (Zeiss).
Statistical analysis
Data are expressed as the mean value ± standard error of
the mean (SEM) of three independent samples. Statis-
tical significance was determined using the two-tailed
Student t test and ANOVA (GraphPad Prism 7, San
Diego, CA, USA). A p value of < 0.05 indicates statistical
significance.
Results
HOXB7 overexpression affects main morphological
features sparing the phenotype of AD-MSC
To investigate whether overexpression of HOXB7 could
influence the performance of AD-MSC, three inde-
pendent AD-MSC samples (AD-MSC 1, AD-MSC 2,
and AD-MSC 3) were transduced with either a vector
encoding full-length human HOXB7 (MIGR1-HOXB7)
(Fig. 1a) or an empty control vector (MIGR1-GFP). In
all cases, high transduction efficiencies were observed
as indicated by a robust GFP signal (> 98% GFP positi-
vity by FACS; Fig. 1b).
HOXB7 expression was quantified in all the transduced
AD-MSC by qRT-PCR. HOXB7 expression levels were
470-fold higher in AD-MSC-HOXB7 compared to control
AD-MSC-GFP (Fig. 1c). After transduction, the cells were
expanded, and their morphology and antigenic profiles
evaluated. HOXB7-related morphological changes were
observed in all three samples. In particular, AD-MSC-
HOXB7 grew to a higher density and retained a smaller
size compared to AD-MSC-GFP, which had larger cyto-
plasmic bodies (Fig. 1d). To validate these observations,
the main AD-MSC physical parameters, such as forward
scatter (FSC) and side scatter (SSC), were analyzed by
FACS. AD-MSC-HOXB7 had a reduced size (FSC) with
lower internal complexity (SSC) (Fig. 1e), suggesting a
change in the AD-MSC cell structure, which was pre-
viously observed for BM-MSC. However, the AD-MSC
immunophenotype was not influenced by HOXB7 overex-
pression. The cells were positive for the main mesenchy-
mal markers (e.g., CD90, CD105, and CD73) and lacked
the expression of hematopoietic antigens, including CD45
and CD14 (Fig. 1f). Collectively, these data indicated that
in vitro amplified AD-MSC that overexpressing HOXB7
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were morphologically changed in vitro but maintained the
typical surface AD-MSC fingerprint.
HOXB7 reduces senescence and facilitates the
proliferation of AD-MSC ex vivo
In an attempt to verify the hypothesis that the improved
cell performance was due to transduced HOXB7 overex-
pression, the in vitro cell expansion was monitored by
the expression of Ki-67, a known proliferation marker
[29, 30]. There was a 3.1-fold increase in Ki-67 expres-
sion in AD-MSC-HOXB7 compared to AD-MSC-GFP
as determined by qRT-PCR, which suggests that
HOXB7 might play a role in the regulation of AD-MSC
proliferation (Fig. 2a). To investigate whether the in-
creased proliferative potential of MSC HOXB7 cells
could be due to change in the cell cycle phases, a cell
cycle analysis was implemented (Fig. 2b). The data re-
vealed an increase, although non-significant, of the S/
G2/M phases in AD-MSC-HOXB7 versus AD-MSC-
GFP. Long-term in vitro proliferation studies instead
showed that AD-MSC-HOXB7 had a greater prolifera-
tion capacity starting from passage 7 (four passages
after viral infection), which indicated a significantly
higher performance compared to the AD-MSC-GFP
(Fig. 2b). The effect of HOXB7 overexpression on the
senescence of AD-MSC was evaluated using SA-ß-Gal
staining. The number of SA-β-Gal positive cells was
higher for the AD-MSC-GFP samples compared to the
AD-MSC-HOXB7 samples (Fig. 2d, e). In order to
validate these findings accounting for known markers
of MSC senescence [31], p21 and p53 were additionally
assessed by qRT-PCR. Interestingly, AD-MSC-HOXB7
significantly downregulated p21 and p53 (Fig. 2f), con-
firming a relation between HOXB7 expression and a re-
duced senescence. These findings collectively suggest that
HOXB7 could alter AD-MSC performance by simultan-
eously increasing proliferation and reducing senescence
involving known molecular pathways.
HOXB7 overexpression increases bFGF secretion by AD-
MSC
To understand the proliferative properties of AD-MSC-
HOXB7, we focused on bFGF as the pivotal MSC mitogen
and known transcriptional target of HOXB7 in cancer
[32] bFGF was highly expressed in AD-MSC-HOXB7
(Fig. 3a), which was confirmed by measuring the levels of
secreted bFGF protein in the AD-MSC-HOXB7 super-
natants after 24 or 48 h in culture (Fig. 3b). These data





Fig. 1 HOXB7 overexpression leads to morphological changes of AD-MSC without affecting the immunophenotypic profile. a MigR1-HOXB7
vector. b Expression of green fluorescent protein (GFP) detected by FACS in three independent AD-MSC samples (AD-MSC 1, AD-MSC 2, AD-MSC
3) transduced with either empty vector (MSC-GFP) or MigR1-HOXB7 (MSC-HOXB7). c Relative HOXB7 expression in AD-MSC-HOXB7 compared to
AD-MSC-GFP. Data are the mean of three biological samples, *p value = 0.001. d Microscopic morphology of the three different biological
samples (AD-MSC 1, AD-MSC 2, AD-MSC 3) either overexpressing HOXB7 (lower panel) or transduced with empty vector (GFP, upper panel), scale
bar 100 μm. e Representative sample analyzed for physical parameters by FACS. f Expression of surface markers CD14, CD45, CD90, CD73, and
CD105 by FACS analysis in AD-MSC-GFP and AD-MSC-HOXB7





Fig. 2 HOXB7 reduces senescence and increases the proliferation potential of AD-MSC ex vivo. a Relative Ki67 expression in AD-MSC-HOXB7
compared to AD-MSC-GFP at passage 9, *p value = 0.02. b Histogram indicating the percentages of the cells in G0/G1, S, and G2/M phases by
FACS analyses. c Cumulative population doubling of AD-MSC-HOXB7 and AD-MSC-GFP calculated from passages 3 to 9. d Representative
SA-β-Gal staining of AD-MSC-GFP (upper panel) and AD-MSC-HOXB7 (lower panel) performed at passage 13 at 4× high power field (n = 10)
(EVOS™ FL Auto Imaging System). Scale bar 400 μm. (e) Quantification of SA-β-Gal positive cells at 2.5× high power field (n = 10), *p value = 1.92E−09.
f Relative expression of senescence-related genes p21 and p53 by qRT-PCR in AD-MSC-HOXB7 compared to AD-MSC-GFP. Data are the mean of three
biological samples, *p value = 0.02, **p value = 0.001
Fig. 3 HOXB7 increases levels of bFGF secretion by AD-MSC. a Relative bFGF expression in AD-MSC-HOXB7 compared to AD-MSC-GFP. Data are
the mean of three biological samples, *p value = 0.003. b Secreted bFGF in the supernatants of AD-MSC-GFP and AD-MSC-HOXB7 after 24 or 48 h
in culture by ELISA experiment. Data are the mean of three biological samples, *p value = 0.03 HOXB7 versus GFP at 24 h and **p value = 0.01
versus GFP at 48 h
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with the AD-MSC populations, which is consistent with
the data for BM-MSC [14].
HOXB7 influences AD-MSC adipogenic differentiation at
the molecular level
Having defined the AD-MSC phenotype, we next assessed
the human AD-MSC adipogenic differentiation potential.
AD-MSC-HOXB7 were incubated with adipogenic in-
duction media. After 10 days, both AD-MSC-GFP and
AD-MSC-HOXB7 differentiated towards the adipogenic
lineage as indicated by the round lipid droplets inside
the cells and positive Oil Red O staining (Fig. 4a). As
expected, no staining was observed in the undifferenti-
ated controls (Fig. 4a). Since there was no difference in
the adipogenic differentiation of AD-MSC-HOXB7 and
AD-MSC-GFP, we performed qRT-PCR to evaluate the
expression of adipocyte-specific genes (Fig. 4b). Inter-
estingly, there were significantly lower levels of PPAR-γ
in the AD-MSC-HOXB7, indicating a less committed




Fig. 4 HOXB7 does not alter AD-MSC adipogenic differentiation but enhance osteogenic potential and favors the chondrogenic potential of AD-
MSC. a Adipogenic differentiation after 10 days of induction visualized by Oil Red O staining in AD-MSC-HOXB7 and AD-MSC-GFP; uninduced
controls (inset). Scale bar 100 μm. (b) Histograms show the mRNA expression of the adipogenic markers PPAR-γ and LPL after induction in AD-MSC-GFP
and AD-MSC-HOXB7. Data are the mean of three biological samples, *p value = 4.90E-06. c Von Kossa staining after osteogenic induction of AD-MSC-GFP
and AD-MSC-HOXB7 (uninduced control, inset). Scale bar 100 μm. ImageJ quantification of the positive stained area on the right; *p value = 2.3E−32
HOXB7 versus GFP after 10 days of induction, **p value = 1.9E−61, and ***p value = 2.4E−80. d mRNA expression of osteogenic markers
ALP (*p value = 0.02), COL1A1, and DCN. Histograms show the relative expression of the markers in AD-MSC-GFP and AD-MSC-HOXB7
after induction. Data are the mean of three biological samples. e Chondrogenic differentiation after 21 days of induction visualized by
Safranin O/Fast Green staining in AD-MSC-GFP and AD-MSC-HOXB7; uninduced controls (inset). Scale bar 100 μm. f Histograms show the
mRNA expression of adipogenic markers COL2A1 and SOX9 in AD-MSC-GFP and AD-MSC-HOXB7 after induction. Data are the mean of
three biological samples, *p value = 0.01 and 0.00008, respectively
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HOXB7 enhances AD-MSC osteogenic potential
Since AD-MSC can differentiate into bone matrix-
producing cells and HOX genes are associated with
prenatal skeletal development [33], we evaluated whether
HOXB7 overexpression could alter the mineralizing
potential of AD-MSC using an rhBMP-2-based in vitro
assay. After 2 weeks of induction, von Kossa staining was
performed on induced and uninduced AD-MSC. The
induced AD-MSC-HOXB7 had a greater mineralization
potential compared to the induced AD-MSC-GFP with
more than a two-fold increase in osteogenic commitment
(Fig. 4c). These cells also had a significant increase in
the expression of a key osteogenic marker, alkaline
phosphatase (ALP), by qRT-PCR. Expression of two add-
itional osteogenic genes (Collagen 1A1 and Decorin) was
also increased, but the changes did not reach statistical
significance, likely due to the large variability among the
biological replicates (Fig. 4d). Overall, these data indicated
increased in vitro mineralization and ALP following
overexpression of HOXB7.
HOXB7 dramatically increases AD-MSC chondrogenesis
The pellet culture system was used to evaluate whether
HOXB7 overexpression might alter the chondrogenic dif-
ferentiation of AD-MSC. AD-MSC-HOXB7 and AD-MSC-
GFP were induced for 21 days and then stained with
Safranin O to detect acid proteoglycan, which is present
in cartilage tissues as indicated by a typical orange-red
color [34]. Histological sections showed a greater accu-
mulation of cartilage-like extracellular matrix and pro-
teoglycan in the induced AD-MSC-HOXB7 compared
to the AD-MSC-GFP. As expected, no staining was
observed in undifferentiated cells (Fig. 4e). To confirm
the histological data, expression levels of the typical chon-
drogenic markers, SOX9 and Collagen 2A1 (COL2A1),
were measured by qRT-PCR. The AD-MSC-HOXB7 had
higher expression of both genes compared to the
AD-MSC-GFP (Fig. 4f). To further validate the greater
chondrogenic commitment of AD-MSC-HOXB7, we
additionally analyzed COL2A1 and ACAN, as mature
chondrogenic markers (Fig. 5). AD-MSC-HOXB7
pellets expressed more COL2A1 and ACAN than
AD-MSC-GFP. All these data support that HOXB7
promotes a robust chondrogenic differentiation in adi-
pose mesenchymal progenitors.
Discussion
The promising therapeutic properties of AD-MSC have
been evaluated in several fields of regenerative medicine
[8, 11]. Over the last several years, progress has been
made in the isolation and morphological characterization
of AD-MSC and in defining their molecular features and
differentiation potential [35, 36]. While deeper preclinical
and clinical studies are still required, it has been demon-
strated how AD-MSC can mediate their therapeutic
effects although their regenerative potential can vary
[36, 37]. In particular, human and animal aging may
negatively impact AD-MSC properties [38, 40]. The
molecular mechanisms behind these events remain
largely obscure, precluding the development of coun-
teracting strategies to limit or abrogate aging that may
influence proliferation, differentiation, and secretion.
Our group has focused on dissecting age- and senescence-
related fingerprints to identify key factors that influence
stem cell senescence to optimize regenerative medicine
and gain a better understanding of human aging. We
recently identified changes in HOXB7 levels as an
age-related factor and master player that drives BM-MSC
proliferation and differentiation [14]. We showed that








Fig. 5 Representative images of AD-MSC-HOXB7 and AD-MSC-GFP pellet cultures stained by the anti-COL2A1 antibody (left panel) and by the
anti-ACAN antibody (right panel) after 21 day of chondrogenic induction. Scale bar 100 μm
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increased proliferation, reduced senescence, and increased
osteogenesis that counteracts the aging that occurs in hu-
man and animal BM-MSC [14, 39, 41–43]. The aim of this
current study was to investigate the impact of HOXB7
overexpression on human AD-MSC. AD-MSC samples
were isolated from lipoaspirates and then expanded,
characterized, and transduced with retroviral vectors
encoding HOXB7 or GFP control. The transduction
efficiency was more than 98% for both HOXB7 and
GFP samples. Interestingly, shortly after transduction,
the cells carrying the HOXB7 encoding vector had a re-
duced proliferation capacity compared to the GFP-only
control cells (not shown). This phase of growth was re-
versible and lasted for 10 days after transduction. After
this period, the HOXB7 overexpressing AD-MSC cells
were more proliferative than the control AD-MSC and
possessed morphological changes (e.g., reduction in cell
size and internal complexity) that are hallmarks of
younger mesenchymal populations [33, 41, 42]. It is
well known that human MSC are heterogeneous with
differently shaped and sized cells; the large ones propa-
gated very slowly and the small ones more rapidly [44].
Thus, the cell size has been considered a relevant par-
ameter in MSC biology: the large cells are referred to
as mature MSC and the smaller ones are referred to as
recycling stem (RS) cells. In addition, MSC aging has
been associated with an increase in cell size [45]. While
further investigations shall be demanded to better
clarify the impact of HOXB7 in MSC size, we may specu-
late that the higher cellular performance identified in the
AD-MSC-HOXB7 compared to AD-MSC-GFP may be
also related with this change in morphology. The molecu-
lar analyses also demonstrated a substantial increase in
Ki-67 levels after HOXB7 overexpression. While this was
not completely aligned with a non-significant increase
S/G2/M phases of AD-MSC-HOXB7, it could be that
HOXB7 may play a different role in primary MSC com-
pared to the tumor cell lines where it acts as oncogene
dramatically increasing cell proliferation [46, 47]. To
our knowledge, there have been no other reports eva-
luating the overexpression of HOX genes or HOXB
family genes to modify adipose progenitors ex vivo.
Therefore, with the limitation of an in vitro approach,
our cells represent a novel tool for potential therapeutic
applications based on adult progenitors. It is well known
that HOX genes play an essential role in prenatal develop-
ment [33]. However, little information is available on the
role of HOX genes in post-natal life (e.g., adult stem cell
regulation). In this respect, HOXB genes have been stud-
ied in other human progenitor compartments, providing
initial evidence of their regulatory functions that might
allow the development of therapeutic strategies to
optimize stem cell self-renewal and commitment [22, 48].
For example, HOXB4 overexpression can enhance the ex
vivo expansion of hematopoietic progenitors and promote
their in vivo regenerative potential by multiple transcrip-
tional activities, leading to the modulation of several target
genes [49]. Similarly, when we overexpressed HOXB7 in
BM-MSC, we observed a decrease in cell size, increased
Ki-67 expression, and decreased senescence with no
changes in their immunophenotypical profile or indica-
tions of malignant transformation [14].
The role of the HOX genes in post-natal life was origin-
ally confirmed by Wagner et al., who found that the ex-
pression of many HOX genes was regulated during aging
with most of these genes age-repressed (e.g., HOXA5,
HOXB3, and HOXB7) or age-induced (e.g., HOXA7,
HOXB5, and HOXB6) in MSC and hematopoietic pro-
genitor cells, respectively [22]. Thus, HOX genes may not
only function in prenatal morphogenesis and differenti-
ation but also during post-natal aging. This has been here
confirmed by the significant downregulation of p21
and p53, as reported by modified AD-MSC expressing
hTERT [50].
Based on our previous studies with BM-MSC and
other previously reported data on the role of HOXB7 in
regulating bFGF expression [14, 15, 32], we focused on
bFGF mRNA and protein expression in the current
study. HOXB7 overexpressing AD-MSC secreted signifi-
cantly higher levels of bFGF, which is consistent with
previously published data on bFGF and suggests that
bFGF is a key player that counteracts aging in mesen-
chymal progenitors [14]. In addition, bFGF appears to be
a driver of MSC differentiation, which influences this
process towards all three mesenchymal lineages [51–55].
Our data revealed that a higher level of secreted bFGF
from AD-MSC-HOXB7 was linked to increased osteo-
genesis and chondrogenesis but had a negligible effect
on adipogenesis. However, there were reduced PPAR-γ
levels of AD-MSC-HOXB7 under adipogenic conditions,
which might indicate a degree of resistance to adipo-
genic differentiation. These cells were able to generate
lipid droplets in vitro, suggesting the persistence of
multipotency in the HOXB7 overexpressing cells.
As demonstrated for BM [14] AD-MSC-HOXB7
showed a greater mineralization potential versus the
induced AD-MSC-GFP with more than a two-fold
increase in osteogenic commitment and a significant
increase of ALP, a key early marker of bone differen-
tiation. The possible role of HOXB7 in MSC osteogenic
commitment has also been described by Gao et al., who
reported that HOXB7 positively affects the osteogenic
potential of BM-MSC through the upregulation of
runt-related transcription factor 2 (RUNX2) and acti-
vation of bone sialoprotein (BSP) [55, 56]. These data
suggest that activation of HOXB7 signaling might favor
bone regeneration by those MSC populations that may
not be primed to easily generate skeletal tissues [56–58].
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Interestingly, in our model, higher chondrogenesis was
enhanced by HOXB7 as determined by gene expression
and histologic analyses of cartilage markers indicating a
higher expression of key chondrogenic markers (e.g., SOX9,
COL2A1, and ACAN). This effect is of particular interest
for possible therapeutic applications and tissue develop-
ment (e.g., cartilage and bone). As reported, a chondrogenic
pre-induction of MSC may enhance bone quality by
endochondral [58, 59]. In a recent study, Janicki et al.
showed that bone quality could be enhanced by chondro-
genic pre-induction of BM-MSC/beta-TCP constructs in
vitro, which triggers differentiation via the endochondral
ossification pathway, attracts hematopoietic marrow more
efficiently, and allows full ossicle formation [54]. In an-
other experiment, BM-MSC and AD-MSC from 14 differ-
ent donors were compared. Brocher et al. reported that
BM-MSC seeded on beta-TCP scaffolds induced new bone
deposition onto the scaffold whereas no bone deposition
was observed with AD-MSC 8 weeks after subcutaneous
implantation. The AD-MSC results were moderately im-
proved by prolonging the observation period to 12 weeks
[58, 59]. Since several studies favored the use of BM-MSC
for osteogenesis and chondrogenesis because of their
presumable pre-commitment towards these lineages, our
results showed that AD-MSC-HOXB7 could overcome
this initial disadvantage. Indeed, HOXB7 overexpression
seemed to favor chondrogenesis as a precondition for
robust osteogenesis. Studies aimed at developing novel
tissue engineering strategies that manipulate the secretion
of the inducing ligand or developmental signaling path-
ways have been reported to improve the clinical efficiency
of MSC [60, 61]. However, to our knowledge, HOX genes
have never been considered in the context of precondi-
tioned cells, which may be relevant for the production of
better performing skeletal tissues, such as the cartilage.
Conclusion
In conclusion, understanding the importance of HOX
genes expression and function will be critical for future
studies involving MSC for regenerative medicine. More-
over, the identification of possible molecular mechanisms
driving aging may contribute to a better understanding of
the age-related disease and the generation of tools to in-
crease ex vivo progenitor performance for improved thera-
peutic benefits.
Abbreviations
ACAN: Aggrecan; AD: Adipose tissue; ALP: Alkaline phosphatase; bFGF: Basic
fibroblast growth factor; BM: Bone marrow; BMP: Bone morphogenetic
protein; CD: Cluster of differentiation; COL1A1: Collagen type I alpha 1 chain;
COL2A1: Collagen type II alpha 1 chain; CPD: Cumulative population
doubling; DCN: DECORIN; FSC: Forward scatter; G-CSF: Granulocyte colony-
stimulating factor; GFP: Green fluorescent protein; HOX: Homeobox;
hTERT: Human telomerase reverse transcriptase; LPL: Lipoprotein lipase;
MSC: Mesenchymal stromal/stem cells; PPAR-γ: Proliferator-activated
receptor-gamma; RS: Recycling stem; RUNX2: Runt-related transcription factor




This work was made possible in parts by grants from the European
Commission FP7/2007-2013 (grant no. 241879) REBORNE Project, from
European Commission H2020 (grant no. 733288) Orthounion Project, from
MIUR “Dipartimenti Eccellenti 2017”, Regione Emilia Romagna: Programma di
Ricerca Regione-Università 2010–2012—Strategic Program Regenerative
Medicine of Cartilage and Bone (grant no. PRUa1RI-2012-007) and Fondazione
Guido Berlucchi.
Availability of data and materials
Please contact author for data requests
Authors’ contributions
EMF contributed to the conception and design, collection and assembly of
data, data analysis and interpretation, and manuscript writing. OC, IM, AM,
GG, AVS, and EV contributed to the collection and assembly of the data and
data analysis and interpretation. EMH contributed to the manuscript writing.
GB, LP, MP, and GDS provided the materials. MD contributed to the
conception and design, financial support, data analysis and interpretation,
manuscript writing, and final approval of the manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
Local ethical committee approved all research activities involving human
subjects (collection of samples and following use for the studies). Patients
gave written informed consent to collection of samples of human material
for research.




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Oncology, Department of Medical and Surgical Sciences for
Children and Adults, University-Hospital of Modena and Reggio Emilia, Via
del Pozzo, 71, 41100 Modena, Italy. 2Division of Plastic Surgery, Department
of Medical and Surgical Sciences for Children and Adults, University-Hospital
of Modena and Reggio Emilia, Modena, Italy. 3Rigenerand srl, Modena,
Medolla, Italy. 4Aflac Cancer and Blood Disorders Center, Children’s
Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta,
GA, USA. 5Technopole of Mirandola TPM, Mirandola, Modena, Italy.
Received: 3 September 2018 Revised: 4 February 2019
Accepted: 1 March 2019
References
1. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF,
Luriá EA, et al. Precursors for fibroblasts in different populations of
hematopoietic cells as detected by the in vitro colony assay method. Exp
Hematol. 1974;2(2):83–92.
2. Guan L, Shaoqing L, Wang Y, Yue H, Liu D, He L, et al. In vitro differentiation
of human adipose-derived mesenchymal stem cells into endothelial-like
cells. Chin Sci Bull. 2006;51(15):1863–8.
3. In ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, FHJ C,
Willemze R, et al. Amniotic fluid as a novel source of mesenchymal stem
cells for therapeutic transplantation. Blood. 2003;102(4):1548–9.
4. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, et al. Endometrial
regenerative cells: a novel stem cell population. J Transl Med. 2007;5:57.
5. Pierdomenico L, Bonsi L, Calvitti M, Rondelli D, Arpinati M, Chirumbolo G, et
al. Multipotent mesenchymal stem cells with immunosuppressive activity
can be easily isolated from dental pulp. Transplantation. 2005;80(6):836–42.
Foppiani et al. Stem Cell Research & Therapy          (2019) 10:101 Page 10 of 12
6. Sabatini F, Petecchia L, Tavian M, Jodon de Villeroché V, Rossi GA,
Brouty-Boyé D. Human bronchial fibroblasts exhibit a mesenchymal
stem cell phenotype and multilineage differentiating potentialities. Lab
Invest. 2005;85(8):962–71.
7. Sellheyer K, Krahl D. Skin mesenchymal stem cells: prospects for clinical
dermatology. J Am Acad Dermatol. 2010;63(5):859–65.
8. D’souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al.
Mesenchymal stem/stromal cells as a delivery platform in cell and gene
therapies. BMC Med. 2015;13:186.
9. Steinert AF, Rackwitz L, Gilbert F, Nöth U, Tuan RS. Concise review: the
clinical application of mesenchymal stem cells for musculoskeletal
regeneration: current status and perspectives. Stem Cells Transl Med.
2012;1(3):237–47.
10. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat
Rev Rheumatol. 2013;9(10):584–94.
11. Trohatou O, Roubelakis MG. Mesenchymal stem/stromal cells in
regenerative medicine: past, present, and future. Cell Reprogramming.
2017;19(4):217–24.
12. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current
trends and future prospective. Biosci Rep. 2015;35(2):e00191. Published 2015
Apr 28. https://doi.org/10.1042/BSR20150025.
13. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and
therapeutic opportunities. Nat Med. 2014;20(8):870–80.
14. Candini O, Spano C, Murgia A, Grisendi G, Veronesi E, Piccinno MS, et al.
Mesenchymal progenitors aging highlights a miR-196 switch targeting
HOXB7 as master regulator of proliferation and osteogenesis. Stem Cells
Dayt Ohio. 2015;33(3):939–50.
15. Seifert A, Werheid DF, Knapp SM, Tobiasch E. Role of Hox genes in stem cell
differentiation. World J Stem Cells. 2015;7(3):583–95.
16. Klein D, Benchellal M, Kleff V, Jakob HG, Ergün S. Hox genes are involved in
vascular wall-resident multipotent stem cell differentiation into smooth
muscle cells. Sci Rep. 2013;3 Available from: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3804857/.
17. Wang KC, Helms JA, Chang HY. Regeneration, repair and
remembering identity: the three Rs of Hox gene expression. Trends
Cell Biol. 2009;19(6):268–75.
18. Giampaolo A, Sterpetti P, Bulgarini D, Samoggia P, Pelosi E, Valtieri M, et al. Key
functional role and lineage-specific expression of selected HOXB genes in
purified hematopoietic progenitor differentiation. Blood. 1994;84(11):3637–47.
19. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et
al. Comparative characteristics of mesenchymal stem cells from human
bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol.
2005;33(11):1402–16.
20. Phinney DG, Gray AJ, Hill K, Pandey A. Murine mesenchymal and embryonic
stem cells express a similar Hox gene profile. Biochem Biophys Res
Commun. 2005;338(4):1759–65.
21. Götherström C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K.
Difference in gene expression between human fetal liver and adult bone
marrow mesenchymal stem cells. Haematologica. 2005;90(8):1017–26.
22. Wagner W, Bork S, Horn P, Krunic D, Walenda T, Diehlmann A, et al. Aging
and replicative senescence have related effects on human stem and
progenitor cells. PLoS One. 2009;4(6):e5846.
23. Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of
damaged tissues. Expert Opin Biol Ther. 2006;6(6):567–78.
24. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage
cells from human adipose tissue: implications for cell-based therapies.
Tissue Eng. 2001;7(2):211–28.
25. James R, Kumbar SG, Laurencin CT, Balian G, Chhabra AB. Tendon tissue
engineering: adipose 1 derived stem cell and GDF-5 mediated
regeneration using electrospun matrix systems. Biomed Mater Bristol
Engl. 2011;6(2):25011.
26. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-
derived mesenchymal stem cells as stable source of tumor necrosis factor–
related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res.
2010;70(9):3718–29.
27. Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, et
al. GMP-manufactured density gradient media for optimized
mesenchymal stromal/stem cell isolation and expansion. Cytotherapy.
2010;12(4):466–77.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
C(T) method. Nat Protoc. 2008;3(6):1101–8.
29. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al.
Immunobiochemical and molecular biologic characterization of the cell
proliferation-associated nuclear antigen that is defined by monoclonal
antibody Ki-67. Am J Pathol. 1991;138(4):867–73.
30. van Dierendonck JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Nuclear
distribution of the Ki-67 antigen during the cell cycle: comparison with
growth fraction in human breast cancer cells. Cancer Res. 1989;49(11):
2999–3006.
31. von Zglinicki T, Petrie J, Kirkwood TBL. Telomere-driven replicative
senescence is a stress response. Nat Biotechnol. 2003;21(3):229–30.
32. Caré A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G, et al.
HOXB7 constitutively activates basic fibroblast growth factor in melanomas.
Mol Cell Biol. 1996;16(9):4842–51.
33. Capecchi MR. Hox genes and mammalian development. Cold Spring Harb
Symp Quant Biol. 1997;62:273–81.
34. Hyllested JL, Veje K, Ostergaard K. Histochemical studies of the
extracellular matrix of human articular cartilage--a review. Osteoarthr
Cartil. 2002;10(5):333–43.
35. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al.
Stromal cells from the adipose tissue-derived stromal vascular fraction and
culture expanded adipose tissue-derived stromal/stem cells: a joint
statement of the International Federation for Adipose Therapeutics and
Science (IFATS) and the International Society for Cellular Therapy (ISCT).
Cytotherapy. 2013;15(6):641–8.
36. Rohban R, Pieber TR. Mesenchymal stem and progenitor cells in
regeneration: tissue specificity and regenerative potential. Stem Cells Int.
2017; [cited 2017 Aug 9]. Available from: http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC5327785/.
37. Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in
regenerative medicine. Transfus Med Hemother. 2016;43(4):268–74.
38. Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT. Donor age
negatively impacts adipose tissue-derived mesenchymal stem cell
expansion and differentiation. J Transl Med. 2014;12:8.
39. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with
decreased maximal life span and accelerated senescence of bone marrow
stromal cells. Bone. 2003;33(6):919–26.
40. Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on
the regenerative properties of bone marrow-, muscle-, and adipose-derived
mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963.
41. Marx JC, Allay JA, Persons DA, Nooner SA, Hargrove PW, Kelly PF, et al.
High-efficiency transduction and long-term gene expression with a murine
stem cell retroviral vector encoding the green fluorescent protein in human
marrow stromal cells. Hum Gene Ther. 1999;10(7):1163–73.
42. Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A,
Loutradis D, et al. Effects of donor age, gender, and in vitro cellular
aging on the phenotypic, functional, and molecular characteristics of
mouse bone marrow-derived mesenchymal stem cells. Stem Cells
Dev. 2011;20(9):1549–61.
43. Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, et al.
Age-related intrinsic changes in human bone-marrow-derived
mesenchymal stem cells and their differentiation to osteoblasts. Aging
Cell. 2008;7(3):335–43.
44. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of
recycling stem cells in cultures of plastic-adherent cells from human bone
marrow. Proc Natl Acad Sci U S A. 2000;97(7):3213–8.
45. Mets T, Verdonk G. In vitro aging of human bone marrow derived stromal
cells. Mech Ageing Dev. 1981;16(1):81–9.
46. Chile T, Fortes MAHZ, Corrêa-Giannella MLC, Brentani HP, Maria DA, Puga
RD, et al. HOXB7 mRNA is overexpressed in pancreatic ductal
adenocarcinomas and its knockdown induces cell cycle arrest and
apoptosis. BMC Cancer. 2013;13:451.
47. Yuan W, Zhang X, Xu Y, Li S, Hu Y, Wu S. Role of HOXB7 in regulation of
progression and metastasis of human lung adenocarcinoma. Mol Carcinog.
2014;53(1):49–57.
48. Carè A, Valtieri M, Mattia G, Meccia E, Masella B, Luchetti L, et al.
Enforced expression of HOXB7 promotes hematopoietic stem cell
proliferation and myeloid-restricted progenitor differentiation.
Oncogene. 1999;18(11):1993–2001.
49. Schiedlmeier B, Santos AC, Ribeiro A, Moncaut N, Lesinski D, Auer H, et al.
HOXB4’s road map to stem cell expansion. Proc Natl Acad Sci U S A. 2007;
104(43):16952–7.
Foppiani et al. Stem Cell Research & Therapy          (2019) 10:101 Page 11 of 12
50. Estrada JC, Torres Y, Benguría A, Dopazo A, Roche E, Carrera-Quintanar L, et
al. Human mesenchymal stem cell-replicative senescence and oxidative
stress are closely linked to aneuploidy. Cell Death Dis. 2013;4:e691.
51. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF-2
enhances the mitotic and chondrogenic potentials of human adult bone
marrow-derived mesenchymal stem cells. J Cell Physiol. 2005;203(2):398–409.
52. Kakudo N, Shimotsuma A, Kusumoto K. Fibroblast growth factor-2
stimulates adipogenic differentiation of human adipose-derived stem cells.
Biochem Biophys Res Commun. 2007;359(2):239–44.
53. Quarto N, Fong KD, Longaker MT. Gene profiling of cells expressing
different FGF-2 forms. Gene. 2005;356:49–68.
54. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E, et al.
Retention of multilineage differentiation potential of mesenchymal cells
during proliferation in response to FGF. Biochem Biophys Res Commun.
2001;288(2):413–9.
55. Gao R-T, Zhan L-P, Meng C, Zhang N, Chang S-M, Yao R, et al.
Homeobox B7 promotes the osteogenic differentiation potential of
mesenchymal stem cells by activating RUNX2 and transcript of BSP. Int
J Clin Exp Med. 2015;8(7):10459–70.
56. Im G-I, Shin Y-W, Lee K-B. Do adipose tissue-derived mesenchymal stem
cells have the same osteogenic and chondrogenic potential as bone
marrow-derived cells? Osteoarthr Cartil. 2005;13(10):845–53.
57. Ena S, Ino J, Neirinck A, Pietri S, Tury A, Bastianelli E. Cell therapy for
bone fracture repair: a comparative preclinical review of mesenchymal
stromal cells from bone marrow and from adipose tissue. J Med Dev
Sci. 2015;1(0):12–26.
58. Brocher J, Janicki P, Voltz P, Seebach E, Neumann E, Mueller-Ladner U, et al.
Inferior ectopic bone formation of mesenchymal stromal cells from adipose
tissue compared to bone marrow: rescue by chondrogenic pre-induction.
Stem Cell Res. 2013;11(3):1393–406.
59. Janicki P, Kasten P, Kleinschmidt K, Luginbuehl R, Richter W. Chondrogenic
pre-induction of human mesenchymal stem cells on beta-TCP: enhanced
bone quality by endochondral heterotopic bone formation. Acta Biomater.
2010;6(8):3292–301.
60. Palmer GD, Steinert A, Pascher A, Gouze E, Gouze J-N, Betz O, et al. Gene-
induced chondrogenesis of primary mesenchymal stem cells in vitro. Mol
Ther J Am Soc Gene Ther. 2005;12(2):219–28.
61. Steinert AF, Palmer GD, Pilapil C, Nöth U, Evans CH, Ghivizzani SC. Enhanced
in vitro chondrogenesis of primary mesenchymal stem cells by combined
gene transfer. Tissue Eng Part A. 2009;15(5):1127–39.
Foppiani et al. Stem Cell Research & Therapy          (2019) 10:101 Page 12 of 12
